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Abstract
Lung diseases are one of the most frequent causes of pulmonary hypertension (PH). The development of PH influences the course of 
lung disease, worsening the clinical symptoms and prognosis. According to the most recent publications, PH in the course of lung 
diseases develops as a result of both “parenchymal” and vascular pathology, in the patients with genetic predisposition. Prolonged 
infection (especially viral one) may be an additional promoting factor. Right heart catheterization (RHC), which is an invasive proce-
dure, is the only objective method of diagnosing PH. According to the latest recommendations, the management algorithm of PH and 
coexisting interstitial lung disease is based on RHC and the results of pulmonary function tests. Majority of the patients develop mild 
PH in the course of advanced lung disease. Best treatment of underlying lung pathology combined with long term oxygen treatment 
is recommended in this group. In case of severe PH (mean resting pulmonary artery pressure (mPAP) ≥ 35 mm Hg) the alternate 
cause of PH has to be sought. PAH-specific drugs use should be limited to patients with severe PH participating in clinical trials.
In this review, the value of various non-invasive methods (echocardiography, radiological examination, exercise capacity and brain 
natriuretic peptides assessment) in the process of screening for PH is presented, and the results of recent randomized clinical 
trials with PAH-specific drugs in patients with diffuse parenchymal lung diseases are discussed.
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Introduction
Lung diseases are one of the most frequent 
causes of pulmonary hypertension (PH). The 
development of PH influences the course of 
lung disease, worsening the clinical symptoms 
and prognosis [1]. Despite much progress in the 
recognition, differential diagnosis and treatment 
of PH, there are still many doubts concerning the 
optimal diagnostic and therapeutic algorithms in 
PH due to lung pathology. In the present review 
we try to summarize the present status of know-
ledge and discuss future directions of research 
in this field.
Classification of PH in the course of diffuse 
parenchymal lung diseases
The latest classification of PH was published 
in JACC after the Fifth World Symposium on 
Pulmonary Hypertension held in Nice in Febru-
ary 2013 [2]. The causes of PH were classified, 
as previously, into 5 groups: 1 — pulmonary 
arterial hypertension (PAH), 2 — PH due to left 
heart disease (venous, postcapillary PH), 3 — PH 
due to lung diseases and/or hypoxia, 4 — chro-
nic thromboembolic pulmonary hypertension 
(CTEPH) and 5 — PH with unclear, multifactorial 
mechanisms (Table 1). The group 1’ consisting of 
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Table 1.  Current classification of pulmonary hypertension [2]
1. Pulmonary arterial hypertension
 1.1. Idiopathic PAH
 1.2. Heritable PAH
  1.2.1. BMPR2
  1.2.2. ALK-1, ENG, SMAD 9, CAV1, KCNK3
  1.2.3. Unknown
 1.3. Drug and toxin induced
 1.4. Associated with:
  1.4.1. Connective tissue disease
  1.4.2. HIV infection
  1.4.3. Portal hypertension
  1.4.4. Congenital heart diseases
  1.4.5. Schistosomiasis
1’ Pulmonary veno-occlusive disease and/or pulmonary capillary  
 hemangiomatosis
1” Persistent pulmonary hypertension of the newborn (PPHN)
2. Pulmonary hypertension due to left heart disease
 2.1. Left ventricular systolic dysfunction
 2.2. Left ventricular diastolic dysfunction
 2.3. Valvular disease
 2.4. Congenital/acquired left heart inflow/outflow tract obstruction 
 and congenital cardiomyopathies
3. Pulmonary hypertension due to lung diseases and/or hypoxia
 3.1. Chronic obstructive pulmonary disease
 3.2. Interstitial lung disease
 3.3. Other pulmonary diseases with mixed restrictive and 
 obstructive pattern
 3.4. Sleep-disordered breathing
 3.5. Alveolar hypoventilation disorders
 3.6. Chronic exposure to high altitude
 3.7. Developmental lung diseases
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
5. Pulmonary hypertension with unclear multifactorial 
 mechanisms
 5.1. Hematologic disorders: chronic hemolytic anemia, 
 myeloproliferative disorders, splenectomy
 5.2. Systemic disorders: sarcoidosis, pulmonary histiocytosis, 
 lymphangioleiomyomatosis
 5.3. Metabolic disorders: glycogen storage disease, Gaucher  
 disease, thyroid disorders, 
 5.4. Others: tumoral obstruction, fibrosing mediastinitis, 
 chronic renal failure, segmental PH
BMPR — bone morphogenic protein receptor type II; CAV1 — caveolin-1; 
ENG — endoglin; HIV — human immunodeficiency virus; PAH — pulmonary 
arterial hypertension
persistent PH of the newborn was additionally 
listed.
According to this classification, PH in the 
course of various diffuse parenchymal lung di-
seases (DPLD) is still listed in different groups: 
due to idiopathic pulmonary fibrosis (IPF), non
-specific interstitial pneumonia (NSIP), other 
types of interstitial pneumonia, hypersensitivity 
pneumonitis (HP), eosinophilic pneumonitis, and 
pulmonary alveolar proteinosis — in the group 3, 
due to sarcoidosis, pulmonary Langerhans cells 
histiocytosis (PLCH), lymphangioleiomyomato-
sis (LAM) and vasculitis — in the group 5, due 
to connective tissue diseases with predominant 
vascular involvement — in the group 1. Such 
classification was a consequence of the belief 
that distinct pathophysiological mechanisms 
were responsible for PH development in different 
nosological types of lung disease, but in the light 
of new experimental data this way of thinking 
may be out of date.
Pathobiology of PH in the course of DPLD
The established model of PH in the course of 
DPLD was the one related to vascular remodeling 
due to interstitial pathology and/or hypoxia [3]. 
Nevertheless, the presence of vascular pathology 
in the areas of minor interstitial lung disease, and 
the occurrence of PH in the early stage of dise-
ase in patients without substantial hypoxemia, 
indicate the more complex pathogenesis. Recent 
studies suggest the role of alveolar epithelial 
cells, fibroblasts, and vascular cells in PH de-
velopment [4]. In IPF the process is initiated by 
fibrocytes bearing CD34 or CD45 markers, derived 
from the bone marrow or from the population of 
pulmonary steam cells, responsible for inducing 
collagen production and recruitment of profi-
brogenic inflammatory mediators [5−7]. The 
process seems to be regulated by a large variety 
of angiogenesis promoters and inhibitors as well 
as growth factors.
The animal model of progressive interstitial 
pulmonary fibrosis and associated pulmonary 
hypertension was described recently by Jarman 
et al. as a result of increased activity of TGFb si-
gnaling pathway [8]. The fibrotic foci adjacent to 
areas of alveolar injury and vascular remodeling 
were combined with profibrotic microenviron-
ment with elevated levels of matrix metallopro-
teinases (MMP2, MMP7 and MMP12), PDGFb 
and chemokines (CCL2, CXCL12), resulting in 
secondary recruitment of macrophages, mast cells 
and fibrocytes [8].
pulmonary veno-occlusive disease (PVOD) and/or 
pulmonary capillary hemangiomatosis (PCH) 
remained unchanged, and group 1” including 
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The pathomorphological signs of lung inju-
ry in humans, with different type and degree of 
concomitant vessels remodeling, depend among 
others, on individual predisposition, probably re-
lated to genetic or epigenetic changes. Hoffman et 
al. described recently the altered genes belonging 
to retinol metabolism pathway or extracellular 
matrix receptor pathway in the lungs explanted 
due to pulmonary hypertension in the course of 
IPF [9].
Viral antigens could play a role in promoting 
vascular changes. Such model of PH was previo-
usly described in HIV patients [10]. Calabrese et 
al. demonstrated lately the presence of herpes 
virus genetic material in lungs of patients with 
IPF, and the correlation between the presence of 
viral material and degree of PH [11].
The pathomorphological analysis of material 
obtained from postmortem examination or from 
explanted lungs of the patients with PH revealed 
the presence of both vascular and parenchymal 
pathology in IPF, sarcoidosis, PLCH and connec-
tive tissue diseases (CTD) [12−15]. The vascular 
changes disproportionate to parenchymal lung 
disease were frequently found in the course of 
CTD [12] and occasionally in sarcoidosis and 
PLCH [14, 15]. On such circumstance, the clini-
cal picture may be more similar to that found in 
PAH, with severe PH and mild lung disease only. 
Moreover, fibrous remodeling of the pulmonary 
veins mimicking PVOD has been frequently found 
in systemic sclerosis (SSc) and PLCH [12, 16] and 
occasionally in IPF and sarcoidosis [13, 14].
On the other hand, an extensive fibrotic 
process in the course of IPF may be responsible 
for mild PH only, observed in the end-stage 
disease. The recognition of different pheno-
types of PH within the population of patients 
with lung diseases will be an important task 
for the future, enabling the classification of PH 
according to dominating pathogenic process in 
lungs, and not according to nosological type 
of disease.
Epidemiology of PH in the course of DPLD
The published data concerning the frequen-
cy of PH on right heart catheterization regarded 
mostly patients with end stage DPLDs, and only 
occasionally with an early stage (Table 2). In IPF, 
PH was found in 8−11% of patients with early 
stage disease [17, 18], 32−46% of those with 
advanced disease [19−21], and even in 86% of 
patients at the time of referral for lung transplan-
tation [22]. In majority of the patients mPAP was 
within 25−40 mm Hg, mPAP, exceeding 40 mm 
Hg was found in only 2−9% of the patients [19, 
20]. The prevalence of PH is probably the highest 
(approaching 50% of the patients) in the distinct 
IPF phenotype — combined pulmonary fibrosis 
and emphysema (CPFE) [23, 24].
In sarcoidosis, overall prevalence of PH 
according to Rizatto et al. was 6% [25], in stage 
IV disease — 38−51% [26, 27], in the patients 
referred for lung transplantation — 73,8% [26].
In PLCH, PH was very common in late stages 
of the disease (92−100%) [15, 16], nevertheless 
there is not much data concerning its early stage.
Among CTD, scleroderma is the one with the 
highest predisposition to PH development. The 
overall prevalence of PAH diagnosed on RHC is 
8−18% [28, 29].
Table 2.  Prevalence of pulmonary hypertension in different interstitial lung diseases (based on RHC evaluation)
Type of ILD Sample size mPAP > 25 mm Hg(%) mPAP > 40 mm Hg(%) Author [ref]
Sarcoidosis 130 54% (venous in 15%) Baughman [27]
Sarcoidosis 50 6% Rizatto [25]
Sarcoidosis end-stage 363 73.8% 36% Shorr [26]
IPF early-stage 61 8% Hamada [17]
IPF early-stage 232 11% Raghu [18]
IPF end-stage 2525 46% 9% Shorr [20]
IPF end-stage 626 43% Modrykamien [21]
IPF end-stage 72 32% 2% Lettieri [19]
SSc 3818 9% Avouac [28]
SSc 1483 15−18% Hunzelman [29]
ILD — interstitial lung disease; IPF — idiopathic pulmonary fibrosis; SSc — systemic sclerosis; mPAP — mean pulmonary artery pressure
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Diagnostic algorithm and differential diagnosis of 
PH in the course of DPLD 
Screening for PH in DPLDs
The only indication for screening for pul-
monary hypertension in the patients without the 
symptoms of PH concerns scleroderma patients 
[30]. The rationale of this approach is combined 
with the possibility of active treatment of PAH 
in this group of patients. The indications for 
screening, established during the Nice Confe-
rence, concern SSc spectrum of diseases (SSc, 
mixed connective tissue disease) with diffusion 
capacity for carbon monoxide (DLCO) ≤ 60% pred. 
and the disease duration exceeding 3 years [30]. 
The proposed algorithm was similar to the one 
published by Coghlan et al. in DETECT study [31]. 
The first step included assessment of the presen-
ce of: telangiectasia, anticentromere antibodies, 
righ-axis deviation on ECG, low DLCO, elevated 
serum of uric acid and increased brain natriu-
retic propeptide (NT-proBNP) concentrations. 
The second step included echocardiographic 
examination, and finally the diagnosis of PH was 
verified by RHC. This algorithm allowed for much 
lower rate of missed PAH cases (4%) comparing 
to the algorithm proposed by European Society 
of Cardiology (ESC) based on echocardiography 
alone (29%) [31]. The value of this approach is 
not known in other CTDs and in patients with 
DLCO > 60% pred.
Early recognition of PH in DPLD
The rationale for the early recognition of PH 
in the course of DPLD is based on several facts:
1. The risk of bleeding during diagnostic lung 
biopsies is higher in PH patients.
2. The presence of PH in the patient with hy-
poxemia is a strong indication for the long 
term oxygen therapy (LTOT).
3. PH significantly worsens the prognosis of 
DPLD and should be taken into account as 
an additional indication for lung transplanta-
tion in end-stage DPLD in otherwise suitable 
patients.
4. The patients with documented severe PH in 
the course of DPLDs have the possibility to 
enter randomized clinical trials with PAH
-specific treatment.
PH in the course of DPLD develops in majority 
of patients in advanced disease stage. Most patients 
complain of worsening dyspnea and limited exerci-
se tolerance. Such symptoms are non-specific and 
may be caused by the progression of DPLD. The 
signs of right ventricular insufficiency, which are 
more specific for PH, indicate the advanced pulmo-
nary hypertension. Thus the attempts of predicting 
PH based on the results of pulmonary function 
tests (PFT), exercise capacity and radiological pre-
sentation have been made by many authors. Most 
published data concern the diagnostic value of: 
plethysmography and DLCO, blood gas analysis, 
exercise capacity, radiological presentation.
Plethysmography and DLCO
The pattern of disturbances in PFT depends 
on the type of DPLD. In sarcoidosis, significant 
PFT abnormalities appear usually in advanced 
stage of the disease (stages III and IV) and con-
cern 60% of patients [32]. The most typical is 
a restrictive PFT pattern ( TLC< lower limit of 
normal — LLN), occasionally with coexisting 
bronchial obstruction (FEV1/FVC< LLN) [32]. An 
obstructive pattern is caused by either bronchial 
hyperreactivity or extrinsic compression of large 
bronchi by enlarged lymph nodes. In the latter 
situation, the obstruction is usually irreversible. 
DLCO is lowered proportionally to PFT disturban-
ces. In HP, a restrictive pattern is predominating; 
nevertheless, large proportion of patients present 
with bronchial obstruction and hyperinflation 
due to air-trapping. Decreased DLCO is a sensitive 
marker of the lung disease. In IPF, the plethysmo-
graphy reveals a restrictive pattern with conco-
mitant DLCO lowering in most cases.
According to many published data, the de-
velopment of PH should be suspected in patients 
with DLCO decreased disproportionally to the 
degree of PFT disturbances [17−20, 33]. The 
criterion of low DLCO used for PH prediction was 
the value below 40% pred. [17].
The other possibility of predicting PH was 
based on carbon monoxide transfer coefficient 
(Kco) value. Kco is diffusing capacity corrected 
for alveolar volume (VA). In patients in whom 
low DLCO is caused mostly by interstitial lung 
disease, DLCO and VA are usually proportio-
nally decreased. If vascular pathology predomi-
nates, the decrease of DLCO is greater than the 
decrease of VA. Thus, in the patients with PH in 
the course of DPLDs, Kco should theoretically 
be lower than in the patients with ILDs witho-
ut PH. Nevertheless, Zisman et al. didn’t find 
significant difference of Kco between the IPF 
patients with PH confirmed by RHC and those 
without PH [33].
The best strategy in everyday practice wo-
uld be close PFT monitoring in DPLD and early 
identification of cases with DLCO decreasing 
disproportionally to volume parameters.
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Resting blood gases analysis and exercise capacity
Most patients with severe PH demonstrate 
low partial oxygen tension of arterialized capil-
lary blood (PaO2), with oxygen hemoglobin satu-
ration (SaO2) lower than 90% [20]. Hypoxemia 
is very sensitive but nonspecific sign of PH, as 
most of the patients with advanced DPLDs pre-
sent with low PaO2 irrespective of the presence 
or absence of PH.
In patients with PH due to DPLD, decreased 
exercise capacity expressed as shortened 6-min 
walk distance and deep desaturation on exertion 
is observed [19, 34]. The exercise capacity stron-
gly depends on the age, thus the actual distance 
covered should be expressed as % predicted 
rather than absolute value.
Radiological examination
Pulmonary hypertension may be suspected 
on base of both conventional chest X-ray examina-
tion and chest computed tomography with angio-
graphy. Conventional chest X-ray demonstrates the 
enlarged cardiac silhouette, wide pulmonary artery 
trunk and main pulmonary arteries with vessels 
narrowing in distal parts of the lungs. The typical 
X-ray presentation of PAH is showed in Figure 1A, B. 
The diagnostic value of chest X-ray in patients with 
DPLDs is, however, low due to interstitial lung 
disease and/or lymphadenopathy (Fig. 2).
The criteria of PH recognition on chest CT 
angiography are composed of: widening of pul-
monary artery (PA) (> 29 mm), with PA to ascen-
ding aorta (AA) size ratio > 1 [35, 36]. Spruijt et 
al. found recently the utility of joint radiological 
criteria: PA/AA ≥ 1 and right to left ventricular di-
mension ≥ 1.2 in predicting precapillary PH [37]. 
The radiological features of PH on chest CT an-
giography in the patient with PAH are presented 
on Figure 3A, B. Nevertheless, in the patients 
with DPLDs, the radiological features of PH are 
usually less expressed than in PAH, and thus 
they are less sensitive in PH diagnosing [33, 38] 
(Fig. 4A−C).
Brain natriuretic peptides
Brain natriuretic peptides (BNP, NT-proBNP) 
are frequently implemented in the diagnostic 
algorithm of PH. The increased serum concen-
tration of NT-proBNP indicates the presence of 
circulatory insufficiency, but doesn’t differentia-
te between left or right heart failure. Handa et. 
et. found that in sarcoidosis patients NT-proBNP 
correlated better with the presence of cardiac 
sarcoidosis than with the presence of PH [39]. 
Wiliams et al. found NT-proBNP exceeding 395 
A
B
Figure 1. Chest X-ray of a patient with idiopathic pulmonary arterial 
hypertension: A — PA, B — lateral. Main pulmonary artery and bilat-
eral pulmonary arteries dilatation. Enlarged right ventricle
Figure 2. Chest X-ray of a patient with usual interstitial pneumonia, 
PA. Reduced lung volume. Bilateral reticular pattern predominantly 
involving the lower lung zones. Enlarged hila
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Figure 3. Contrast enhanced chest CT of a patient with idiopathic 
pulmonary arterial hypertension, mediastinal window. Enlarged main 
pulmonary artery (A) and right ventricle (B)
pg/ml to be a specific marker of PH in scleroder-
ma patients (95%); unfortunately, the sensitivity 
of this cut off value was only 56% [40].
Palazzuoli et al. showed that BNP > 50 pg/ml 
had 77% of sensitivity and 81% of specificity in 
recognition of PH in the patients with DPLDs 
participating in ARTEMIS-IPF study [41]
Allanore et al. tried to combine NT-proBNP 
with Kco %pred for prediction of PAH in SSc. 
NT-proBNP > 97th percentile of normal and 
Kco < 60% pred. were independent predic-
tors of PH [42]. The authors concluded that 
universal NT-proBNP cut off is impossible to 
establish due to its age and sex dependence 
[42]. Nevertheless, Thakkar et. al. found that 
NT-proBNP ≥ 209.8 pg/ml and/or DLCO < 70% 
pred. and FVC/DLCO ≥ 1.82 were the sensitive 
(100%) and specific (78%) indicators of PAH 
in SSc [43].
A
B
Figure 4. Contrast enhanced chest CT of a patient with sarcoidosis with 
lung fibrosis, lung window (A — retraction of the hilar due to irregular re-
ticular and linear opacities; traction bronchiectasis) and mediastital win-
dow (B, C — features of pulmonary hypertension: dilatation of central 
pulmonary arteries and right ventricle; enlargement of hilar lymph nodes)
 
A
C
B
Echocardiographic examination
Echocardiography is the most frequently 
used noninvasive modality for the recognition 
of PH in DPLDs. Right ventricle systolic pressure 
(RVSP) and pulmonary artery systolic pressure 
(PASP) are calculated using the maximal velocity 
of tricuspid regurgitation jet [44]. The probability 
of PH based on PASP, according to ESC guidelines, 
is presented in table 3 [44]. Greiner et al. found 
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Table 3.  Criteria for pulmonary hypertension based on echocardiography according to ESC [44]
 TRV [m/sec] PASP [mm Hg] Additional PH variables sugge-
stive of PH*
Probability
≤ 2.8 ≤ 36 Lacking PH unlikely
≤ 2.8 ≤ 36 Present PH possible
2.9−3.4 37−50 Lacking
> 3.4 >50 Present or lacking PH likely
*Increased velocity of pulmonary vave regurgitation, short acceleration time of RV ejection into the PA, increased dimensions of right heart chambers, abnormal 
shape and movement of interventricular septum, increased RV wall thickness, dilated main PA; TRV — tricuspid regurgitation velocity; PASP — pulmonary artery 
systolic pressure; PH — pulmonary hypertension; PA — pulmonary artery; RV — right ventricle
SPAP > 36 mm Hg indicative of PAH on RHC 
with 87% sensitivity, 79% of specificity, 91.5% 
of PPV and 70% of NPV in 99 PAH patients [45]. 
Nevertheless, the diagnostic value of echocardio-
graphy in DPLDs is uncertain. The comparison 
between echocardiographic measures and the 
parameters obtained on RHC in the patients with 
lung diseases revealed the discordant results 
(both underestimation and overestimation) in 
50−60% of patients [46, 47]. The optimal RVSP 
cut off value predictive for PH could not be found 
by Nathan et. al. in IPF patients; RVSP > 50 mm 
Hg had 50% sensitivity, 68% specificity, 45% PPV 
and 72% NPV for the recognition of PH [47].
Right heart catheterization
Right heart catheterization (RHC) is the only 
objective method of diagnosing PH. PH in the 
course of lung diseases belongs to the category 
of precapillary pulmonary hypertension, which 
is defined as mPAP equal or higher than 25 mm 
Hg, pulmonary artery occlusion pressure (PAOP) 
not exceeding 15 mm Hg, and pulmonary vascular 
resistance (PVR) higher than 3 Wood units [1].
RHC is mandatory in the differential diagnosis 
of PAH; nevertheless, in patients with PH due to lung 
diseases the indications for RHC should take into 
account the possible therapeutic gain for a patient. 
Taking this into consideration RHC is recommended:
1. In end stage lung diseases during the pro-
cedure of listing for lung transplantation, 
especially in the cases with the suspicion of 
concomitant left heart insufficiency.
2. In patients with echocardiographic suspicion 
of severe pulmonary hypertension in the co-
urse of lung diseases, to exclude the possible 
influence of left heart insufficiency.
3. In patients who are candidates to randomized 
clinical trials with PH-specific drugs.
In Nice, the experts decided to abandon the 
term ’out of proportion PH’ in the course of lung 
diseases and replaced it with the term ’severe 
PH’[1], which was defined as:
— mPAP equal or higher than 35 mm Hg or 
— mPAP equal or higher than 25 mm Hg with 
CI < 2 l/min/m2.
The document covering this issue was de-
dicated to COPD, IPF and CPFE. Severe PH in 
respiratory diseases listed in the group 3 of PH 
classification was characterized recently as sepa-
rate phenotype of PH in the Official Statement of 
American Thoracic Society [48].
It remains uncertain whether the same clas-
sification of PH should be applied for the DPLD 
listed in the group 5 (sarcoidosis, PLCH, LAM, 
vasculitis). 
Severe pulmonary hypertension has been dia-
gnosed in 2-9% of patients with end-stage DPLDs 
[19, 20]. In such situation, the possible influence 
of other factors such as venous thromboembolic 
disease and left heart failure should be excluded.
Recently, Dalleywater et al. found the proba-
bility of pulmonary embolism (PE) six times hi-
gher and the probability of deep vein thrombosis 
doubled during 1.7 years of observation in 3211 
IPF patients compared to controls adjusted for 
age, sex, and smoking habit [49]. Swigris et al. fo-
und that PE as the cause of death was significantly 
more frequent in sarcoidosis patients comparing 
to others (2.54% and 1.13% respectively) [50]. 
Vorselaars et al. found PE in 6.2% of the patients 
with severe sarcoidosis requiring immunosup-
pressive therapy other than corticosteroids [51].
There is no consensus regarding the diagnostic 
algorithm of VTE in DPLDs , but it seems reaso-
nable to use chest CT with angiography as initial 
modality. The utility of ventilation-perfusion scin-
tigraphy in the patients with DPLDs is uncertain.
The frequent clinical problem is the exc-
lusion of left heart insufficiency (especially the 
one with preserved left ventricular ejection frac-
tion on echocardiographic examination) as the 
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Table 5.  Differential diagnosis between group 1 (PAH) and group 3 (PH due to lung diseases) [1]
Criteria suggestive of PAH Parameter Criteria suggestive of PH due to lung disease
Normal or mildly impaired
FEV1 > 60% pred. (COPD)
FVC > 70% pred. (IPF)
Pulmonary function 
tests
Moderate to very severly impaired
FEV1 ≤ 60% pred. (COPD)
FVC ≤ 70% pred. (IPF)
Absence of or only modest abnormalities HRCT Characteristic airway and/or parenchymal abnormalities
Features of exhausted circulatory reserve, preserved 
breathing reserve
Reduced oxygen pulse
Low CO/VO2 slope
Mixed venous oxygen saturation at lower limit
No change or decrease in PaCO2 during exercise
Exercise cardiopulmo-
nary test and right heart 
catheterization
Features of exhausted ventilatory reserve, reduced  
breathing reserve,
Normal oxygen pulse, 
Normal CO/VO2 slope
Mixed venous oxygen saturation above lower limit
Increase in PaCO2 during exercise
 CO — cardiac output; VO2 — oxygen consumption ratio; PaCO2 — partial pressure of carbon dioxide in arterial blood; HRCT — high resolution CT scan; FEV1 — forced 
expiratory volume in 1 sec; FVC — forced vital capacity; IPF — idiopathic pulmonary fibrosis; COPD — chronic obstructive pulmonary disease; PAH — pulmonary 
arterial hypertension; PH — pulmonary hypertension
Table 4. Various causes of PH in the patients with interstitial lung diseases
Type of ILD Lung disease and/ 
/or hypoxia
VTE Left heart disease PAH phenotype PVOD phenotype
IPF +++ + ++ + +
Sarcoidosis +++ + ++ ++ +
Sysytemic sclerosis ++ + ++ +++ ++
PLCH ++ ? ? ++ +
LAM ++ ? ? ++ ?
+++ most probable; ++ probable; + possible
IPF — idiopathic pulmonary fibrosis; PLCH — pulmonary Langerhans cells histiocytosis; LAM — lymphangioleiomyomatosis; VTE — venous thromboembolism; PAH 
pulmonary arterial hypertension; PVOD — pulmonary veno-occlusive disease
coexisting cause of PH in the patients with DPLDs 
[52]. The gold standard is the PAOP measurement 
on RHC, the values exceeding 15 mm Hg indicate 
the presence of postcapillary PH. The role of fluid 
loading or exercise testing in diagnosis of occult 
left heart disease requires further standardization 
and validation [52].
The factors possibly influencing PH in the 
patients with various DPLDs are presented in 
Table 4.
As mentioned before, the most difficult dia-
gnostic challenge is to differentiate between the 
PAH with coexisting lung disease and severe 
PH in the course of lung disease. Badesch et al. 
found COPD as coexisting pathology in 25% of 
the PAH patients in REVEAL registry [53]. The 
radiological signs of DPLD in PAH patients is 
the common clinical problem. Trip et al. found 
mild or moderate fibrosis on HRCT in 12% of the 
patients with IPAH [54].
The algorithm of differential diagnosis pro-
posed during the PH Conference in Nice is based 
on PFT results, HRCT, cardiopulmonary exercise 
test and RHC (Table 5) [1]. The phenotype sugge-
stive of pulmonary arterial hypertension in a pa-
tient with DPLD includes following features: mild 
disturbances on PFT (in IPF — FVC higher that 
70% pred.), absence or only modest parenchy-
mal abnormalities in HRCT, signs of exhausted 
circulatory reserve at the end of exercise (low 
mixed venous oxygen saturation and reduced 
slope of cardiac output/oxygen consumption 
ratio) with breathing reserve maintained (low 
arterial PaCO2) [1].
Treatment considerations of PH  
in the course of DPLDs
According to previous ESC guidelines, pa-
tients with PH in the course of DPLDs should 
receive the best treatment for underlying lung di-
sease [44]. Long term oxygen therapy is indicated 
in case of hypoxemic respiratory insufficiency; 
nevertheless, there is no proof that such treatment 
results in the prolongation of life in the patients 
with PH in the course of DPLD [44]. The patients 
with end-stage DPLDs who are suitable for lung 
transplantation should be referred to transplan-
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Table 6.  Recommendations concerning management of PH in the patients with lung diseases [1]
Clinical characteristics mPAP < 25 mm 
Hg
mPAP 25−34 mm Hg mPAP ≥ 35 mm Hg
FEV1 ≥ 60% pred. (COPD)
FVC ≥ 70% pred. (IPF)
HRCT: absence of or mo-
dest abnormalities
No PH, 
No PAH specific 
treatment recom-
mended
PH classification uncertain
No data supporting treat-
ment with PAH specific 
drugs
PH classification uncertain: discrimination between PAH 
with concomitant lung disease (group 1) or PH caused by 
lung disease (group 3)
Refer to a center with expertise in both PH and chronic lung 
disease
FEV1 < 60%pred. (COPD)
FVC < 70% pred. (IPF)
HRCT: Combined pulmo-
nary fibrosis and emphy-
sema 
No PH
No PAH specific 
treatment recom-
mended
PH-COPD, PH-IPF,  
PH- CPFE
No data currently suport 
treatment with PAH-speci-
fic drugs
Severe PH-COPD, severe PH-IPF, severe PH-CPFE
Refer to a center with expertise in both PH and chronic lung 
disease for individualized patient care because of poor prog-
nosis: randomized controlled trials required
mPAP — mean pulmonary artery pressure; HRCT — high resolution computed tomography; FEV1 — forced expiratory volume in 1 sec; FVC — forced vital capacity; 
IPF — idiopathic pulmonary fibrosis; COPD — chronic obstructive pulmonary disease; CPFE — combined pulmonary fibrosis and emphysema; PAH — pulmonary 
arterial hypertension; PH — pulmonary hypertension
Table 7.  Randomized clinical trials concerning the use of PAH-specific drugs in the patients with interstitial lung diseases
Author [ref] Type of ILD Type of  
treatment 
RCT  
duration
No of pts RHC Primary end-point Result
King [55] IPF Bosentan 12 months 154 No data 6MWT neg
Zisman [57] IPF Sildenafil 12 weeks 180 No data Increase of 6MWD > 20% neg
King [56] IPF Bosentan 12 months 616 No data Time to progression neg
Raghu [18] IPF Ambrisentan 35 weeks 492 11%PH Time to progression closed
Raghu [59] IPF Macitentan 12 months 178 No data Change of FVC neg
Han [58] IPF Sildenafil 12 weeks 119 Echo: RVSD 
in 19%
6MWD In RVSD
+99 meters
p = 0.04
Corte [61] fNSIP
IPF
Bosentan 16 weeks 60 mPAP >
25 mm Hg
PVR neg
Baughman
[60]
Sarcoidosis Bosentan 12 months 35 mPAP >
25 mm Hg
mPAP −4 mm Hg
< 0.02
ILD — interstitial lung disease; RCT — randomized clinical trial; IPF — idiopathic pulmonary fibrosis; fNSIP — fibrotic non-specific interstitial pneumonia; RVSD — right 
ventricle systolic dysfunction; mPAP — mean pulmonary artery pressure; PVR — pulmonary vascular resistance
tation centers. The presence of severe PH in the 
course of end-stage lung disease substantially 
worsens the survival, especially in the patients 
with IPF and CPFE, thus they should be referred 
for lung transplantation without any delay.
The recommendations from Nice Conference 
concerning treatment of PH in lung diseases are 
summarized in table 6 [1]. PAH-specific treatment 
is not recommended in the patients with mild PH 
at rest (mPAP 25−34 mm Hg). The patients with 
severe PH (mPAP ≥ 35 mm Hg) should be refer-
red to the centers with expertise in both PH and 
chronic lung diseases. In patients with mild re-
striction (FVC > 70% pred.), the alternative factor 
influencing PH should be searched. In those with 
FVC < 70% pred., the personalized treatment 
decisions are required. According to published 
recommendations, the subsets of patients with 
FVC < 70% and low or normal cardiac output, 
not adequately increasing on exercise, should be 
preferably included in randomized clinical trials 
(RCT) with PAH specific drugs [1].
The overview of RCT with PAH-specific dru-
gs, published between 2008 and 2014, indicates 
that the patients participating in many trials 
were not the proper candidates for PAH-specific 
treatment (Table 7).
The largest RCT trials, Build 1 and Build 3, 
investigated the efficacy of one year bosentan 
therapy in IPF patients [55, 56]. Unfortunately, 
neither echocardiographic assessment of PH nor 
RHC was performed. The primary end point of 
the first study (improvement of 6 minutes walking 
distance) was not achieved [55]. The second study 
used as a primary end-point time to IPF worse-
ning, defined as IPF acute exacerbation, death, 
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decrease of FVC ≥ 10% or DLCO ≥ 15% [56]. This 
study was also negative. The subgroup analysis 
revealed that bosentan was more effective in the 
patients with less PFT compromise [56].
Zisman et al. investigated the effect of Sil-
denafil in the end-stage IPF patients with DLCO 
< 35% pred (STEP-IPF study) [57]. This study was 
also lacking RHC. The primary end point (6MWD ≥ 
20% improvement) was not achieved, either [57]. In 
2013, Han et al. published the results of sub-study of 
STEP-IPF that included 119 patients in whom echo-
cardiography was available [58]. In 19% of them the 
signs of right ventricle systolic failure was present. 
This group achieved a significant improvement in 
the course of sildenafil treatment, with less decrease 
of 6MWD compared to placebo, p = 0.01 [58].
Another negative study was published by 
Rhagu et al., who investigated the effect of ma-
citentan in IPF patients (Music Trial) [59]. The 
primary endpoint (FVC change) was not achieved.
The inclusion criteria of recently published 
trials applied hemodynamic assessment ( with PH 
defined as mPAP > 25 mm Hg). Baughman et al. 
investigated the effect of bosentan in sarcoidosis 
patients with PH confirmed on RHC [60]. The 
primary end point was mPAP assessed after 16 
week of treatment. The trial was positive, mPAP 
in the treatment group decreased by mean of 4 
mm Hg compared to placebo group, p = 0.01 [60].
Corte et al. assessed the effect of bosentan in 
fibrotic NSIP and IPF with PH confirmed on RHC. 
The primary outcome was the fall of pulmonary 
vascular resistance by 20% or more over 16 weeks. 
The study was negative [61].
According to recent recommendations, the 
candidates to PAH specific treatment should be re-
cruited from the population with severe PH (mPAP 
p ≥ 35 mm Hg) [1]. There is no data about such trial 
in DPLDs , nevertheless Saggar et al,. who used in-
travenous treprostinil in 15 patients with end-stage 
IPF and severe PH, as a bridging to transplantation, 
observed the positive effect on RHC [62].
The most important adverse effect of PAH- 
-specific treatment in the patients with lung dise-
ases was hypoxemia, resulting from the inhibition 
of hypoxic pulmonary vasoconstriction in the 
poorly ventilated lung areas [63].
Hoeper et al. reported the decrease of SaO2 
by 1−2% from baseline in the patients with PH 
(mPAP > 30 mm Hg) in the course of DPLDs tre-
ated with Riociguat in the observational study 
[64]. Nevertheless, mixed venous oxygen satura-
tion slightly increased.
Corte et al. didn’t observe any significant 
difference in the oxygen saturation and oxygen 
requirement between bosentan and placebo gro-
ups in the patients with IPF and fibrotic NSIP 
[61]. Zisman et al. found improved oxygenation 
in the group of IPF patients treated with Sildenafil 
in the STEP-IPF study [57].
These data indicate that the oxygenation may 
behave differently during treatment of DPLDs 
with PAH-specific drugs. Probably the largest 
desaturation occurs in the patients with the most 
severe pulmonary disease. On the other hand, in 
the patients with severe PH and less severe lung 
disease, the improvement of cardiac output in the 
course of PAH-specific treatment may balance the 
saturation decrease due to vasodilatation. Thus, 
in our opinion, the candidates for the future RCT 
of PAH-specific treatment should be rather recru-
ited from the population with PAH-like phenotype 
(mild respiratory disease but severe PH).
Another important issue is the duration of 
studies and the projected end-points [65]. Taking 
into consideration the results obtained in the 
group of PAH patients, the hemodynamic indices 
and the walking distance may not be the sufficient 
indicators of the treatment success. The objective 
end-points of RCT in the patients with PH due to 
DPLDs, should be the survival time without cli-
nical worsening combined with overall survival 
and transplantation rate.
The patients with PH coexisting with end
-stage lung disease are probably heterogeneous 
population. Those in whom the decreased life 
expectancy is caused by exhausted circulatory 
reserve could benefit from the PAH-specific tre-
atment in the future.
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